Edward Tenthoff
Stock Analyst at Piper Sandler
(3.57)
# 729
Out of 5,178 analysts
197
Total ratings
42%
Success rate
7.04%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | $24 | $11.83 | +102.87% | 1 | Mar 24, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 → $110 | $47.09 | +133.60% | 8 | Mar 17, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $45 → $58 | $29.90 | +93.98% | 3 | Mar 13, 2026 | |
| IBRX ImmunityBio | Reiterates: Overweight | $7 → $12 | $8.07 | +48.70% | 1 | Mar 4, 2026 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $10 → $6 | $1.73 | +246.82% | 1 | Feb 25, 2026 | |
| ARVN Arvinas | Reiterates: Overweight | $16 → $20 | $10.92 | +83.15% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Overweight | $63 → $69 | $53.54 | +28.88% | 14 | Feb 23, 2026 | |
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.07 | +93.24% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $15.71 | +135.52% | 4 | Jan 14, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $100 → $110 | $60.77 | +81.01% | 14 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $1.52 | +426.32% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $98 → $125 | $78.93 | +58.37% | 5 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 → $23 | $6.98 | +229.51% | 6 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 → $6 | $1.54 | +289.61% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $449 → $489 | $328.70 | +48.77% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $5.21 | +130.33% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.75 | +152.63% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $10.19 | +47.20% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $23.50 | -14.88% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.22 | +473.77% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.98 | +152.90% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.65 | +53.35% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $17.60 | +343.18% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.40 | +141.94% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $1.74 | +3,635.63% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $0.62 | +3,101.02% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.19 | +152.10% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.26 | +1,035.50% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.22 | +391.80% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.25 | +300.00% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $4.09 | +2,100.49% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $9.14 | +1,869.37% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $15.91 | +176.56% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $4.68 | +690.60% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $4.43 | +264,894,815.25% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $697.05 | -49.21% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $454.97 | -29.01% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.17 | +145.82% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $42.79 | -15.86% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.34 | +1,765.67% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.57 | +26,215.79% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.40 | +3,431,882.09% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $749.47 | - | 11 | Feb 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $882 → $1,064 | $10.68 | +9,862.55% | 2 | Apr 15, 2013 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: $24
Current: $11.83
Upside: +102.87%
CRISPR Therapeutics AG
Mar 17, 2026
Reiterates: Overweight
Price Target: $105 → $110
Current: $47.09
Upside: +133.60%
Capricor Therapeutics
Mar 13, 2026
Reiterates: Overweight
Price Target: $45 → $58
Current: $29.90
Upside: +93.98%
ImmunityBio
Mar 4, 2026
Reiterates: Overweight
Price Target: $7 → $12
Current: $8.07
Upside: +48.70%
Cardiff Oncology
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $6
Current: $1.73
Upside: +246.82%
Arvinas
Feb 25, 2026
Reiterates: Overweight
Price Target: $16 → $20
Current: $10.92
Upside: +83.15%
Moderna
Feb 23, 2026
Maintains: Overweight
Price Target: $63 → $69
Current: $53.54
Upside: +28.88%
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.07
Upside: +93.24%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $15.71
Upside: +135.52%
Arrowhead Pharmaceuticals
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $60.77
Upside: +81.01%
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $1.52
Upside: +426.32%
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $78.93
Upside: +58.37%
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $6.98
Upside: +229.51%
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.54
Upside: +289.61%
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $328.70
Upside: +48.77%
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.21
Upside: +130.33%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.75
Upside: +152.63%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $10.19
Upside: +47.20%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $23.50
Upside: -14.88%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.22
Upside: +473.77%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.98
Upside: +152.90%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.65
Upside: +53.35%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $17.60
Upside: +343.18%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.40
Upside: +141.94%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $1.74
Upside: +3,635.63%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $0.62
Upside: +3,101.02%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.19
Upside: +152.10%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.26
Upside: +1,035.50%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.22
Upside: +391.80%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.25
Upside: +300.00%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $4.09
Upside: +2,100.49%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $9.14
Upside: +1,869.37%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $15.91
Upside: +176.56%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $4.68
Upside: +690.60%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $4.43
Upside: +264,894,815.25%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $697.05
Upside: -49.21%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $454.97
Upside: -29.01%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.17
Upside: +145.82%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $42.79
Upside: -15.86%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.34
Upside: +1,765.67%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.57
Upside: +26,215.79%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.40
Upside: +3,431,882.09%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $749.47
Upside: -
Apr 15, 2013
Maintains: Neutral
Price Target: $882 → $1,064
Current: $10.68
Upside: +9,862.55%